CUMBERLAND PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
| Cumberland Pharmaceuticals Inc. Shareholders | |||||
|---|---|---|---|---|---|
| Common stock · Accumulated deficit · Non-controlling interest · Total equity | |||||
| Shares · Amount | |||||
| Balance, December 31, 2021 | 14,742,754 | $48,452,906 | $(5,638,600) | $(212,328) | $42,601,978 |
| Net loss | — | — | (5,570,241) | (79,798) | (5,650,039) |
| Return of common stock - Methotrexate | (180,000) | (399,600) | — | — | (399,600) |
| Share-based compensation | 171,655 | 447,503 | — | — | 447,503 |
| Repurchase of common shares | (367,793) | (1,025,836) | — | — | (1,025,836) |
| Balance, December 31, 2022 | 14,366,616 | $47,474,973 | $(11,208,841) | $(292,126) | 35,974,006 |
| Net loss | — | $— | (6,279,320) | (51,446) | (6,330,766) |
| Share-based compensation | 157,360 | $365,040 | — | — | 365,040 |
| Repurchase of common shares | (402,143) | $(748,411) | — | — | (748,411) |
| Balance, December 31, 2023 | 14,121,833 | $47,091,602 | $(17,488,161) | $(343,572) | $29,259,869 |
See accompanying notes to consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.